# A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

Source: https://onco.cc/trials/nct07197554/  
OnCo record `nct07197554` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of ST-01156 run by SEED Therapeutics, Inc., now recruiting.

## Summary

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies is a phase 1 interventional study registered as NCT07197554 by SEED Therapeutics, Inc., with 171 participants planned, started 2025-12-01. Conditions recorded: Advanced Solid Tumors, Ewing Sarcoma, Hepatocellular Carcinoma (HCC) and Biliary Tract Cancer (BTC). Interventions recorded: ST-01156.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07197554
- Phase: 1
- Setting: A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
- Sponsor: SEED Therapeutics, Inc.
- Enrolled: 171

## Sources

- ClinicalTrials.gov NCT07197554: https://clinicaltrials.gov/study/NCT07197554

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Ewing sarcoma](https://onco.cc/cancers/ewing-sarcoma/), [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/), [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [ST-01156](https://onco.cc/drugs/st-01156/)
- companies: [SEED Therapeutics](https://onco.cc/companies/seed-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07197554.json